A Simple and Sensitive Assay for Determination of Human Anti-Idiotypic Anti-B72.3 Antibodies, Which is Not Affected by the Presence of Tumour-Associated Glycoprotein 72

Clinical Chemistry and Laboratory Medicine

Volumn 34, Issue 3, 1996, Pages 237-244

  Reinsberg, Jochen ^a   Schmolling, Jan ^a   Ackermann, Dietlind ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY B.72.3; TUMOR PROTEIN;

ACCURACY; ANTIBODY TITER; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DILUTION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNORADIOMETRIC ASSAY; ISOTOPE LABELING; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; CALIBRATION; CROSS REACTIONS; FEMALE; GELS; GLYCOPROTEINS; HUMANS; IMMUNODIFFUSION; IMMUNOGLOBULIN G; IMMUNORADIOMETRIC ASSAY; MICE; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS;

MURINAE;

EID: 0029919285     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1996.34.3.237     Document Type: Article

References (23)

1. Koprowsky H, Herlyn D, Lübeck M, DeFreitas E, Sears HF. Human anti-idiotypic antibodies in cancer patients: is the modulation of the immune response beneficial for the patients?. Proc Natl Acad Sei USA 1984; 81: 216-219.
2. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125: 373-389.
3. Fagerberg J, Frödin JE, Ragnhammar P, Steinitz M, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (abi). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAB therapy?. Cancer Immunol Immunother 1994; 38: 149-159.
4. Coutenay-Luck NS, Epenetos AA, Sivolapenko BG, Lärche M, Barkans JR, Ritter MA. Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988; 15: 894-897.
5. Wettendorf M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Kpprowsky H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO 17-1 A. Proc Natl Acad Sei USA 1989; 86: 3787-91.
6. Frödin JE, Faxas ME, Hagström B, Lefvert AK, Masucci G, Nilsson B, et al. Induction of anti-idiotypic (ab2) and anti-antiidiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome-an important antitumoral effector function? Hybridoma 1991; 10: 421-426.
7. Reinsberg J. Idiotypic cascades after MAb OC125 application. Hybridoma 1993; 12: 577-582.
8. Wagner U, Oehr P, Reinsberg J, Schmidt S, Schlebusch H, Werner A, Krebs D. Immunotherapy of advanced ovarian carcinomas by the activation of the idiotypic network. Biotech Therapeutics 1992; 3: 81-89.
9. Schmolling J, Reinsberg J; Wagner ü, Krebs D. Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3. Hybridoma 1995; 14: 183-186.
10. Herlyn DM, Lübeck M, Sears H, Koprowski H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985; 85: 27-38.
11. Wagner U, Reinsberg J, Oehr P, Briele B, Schmidt S, Werner A, et al. Clinical courses of patients with ovarian carcinomas after induction of anti-idiotypic antibodies against a tumor-associated antigen. Tumordiagn Ther 1990; 11: 1-4.
12. Mäher VE, Drukman SJ, Kinders RJ, Hunter RE, Jennings J, Brigham C, et al. Human antibody response to the intravenous and intraperitoneal administration of the F(ab1)2 fragment of the OC125 murine monoclonal antibody. J Immunotherapy 1992; 11: 56-66.
13. Moseley KR, Knapp RC, Haisma HJ. An assay for detection of human anti-murine immunoglobulins in the presence of CA 125 antigen. J Immunol Methods 1988; 106: 1-6.
14. Ferroni P, Milenic DE, Schlom J, Colcher D. Assay for detection of anti-idiotypic antibodies to monoclonal antibody B72.3. J Clin Lab Anal 1990; 4: 465-473.
15. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46: 3118-24.
16. Thor A, Gorstein F, Ohuchi N, Szpak CA, Johnston WW, Schlom J. Tumor associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 1986; 76: 995-1006.
17. Guadagni F, Roselli M, Amato T, Cosimelli M, Pern P, Casale V, et al. CA-72-4 measurement of tumor-associated glycoprotein-72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res 1992; 52: 1222-7.
18. Esposito G, Panza N, Mansi L, De Matteis A, D'Aiuto G, Labonia V, et al. Evaluation of TAG 72 as a serum marker in ovarian and breast carcinoma. J Nucl Med Allied Sei 1990; 34: 88-93.
19. Reinsberg J, Gast B, Schmolling J, Wagner U, Krebs D. Specific interferences with the determination of the Tumor Associated Glycoprotein 72 (TAG-72) by human antiidiorypic antibodies formed after treatment with the anti-TAG-72 antibody B72.3. Eur J Clin Chem Clin Biochem 1994; 32: 691-696.
20. Schmidt S. Antibody targeted photodynamic therapy. Hybridoma 1993; 12: 539-541.
21. Radparvar S, Fung G, Ngo TT. Simple, quick and efficient site directed antibody immobilization in a cartrige. Biotechniques 1990; 9: 632-635.
22. Bublok W, Passing H, Bender R, Schneider B. A general re gression procedure for method transformation. J Clin Chem Clin Biochcm 1988; 26: 783-790.
23. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-as sociated glycoprotein 72 antigen. Cancer Res 1988; 48: 4588-96.